Influenza vaccine effectiveness against influenza A subtypes in Europe: results from the 2021–22 I-MOVE primary care multicentre study

Esther Kissling, Marta Valenciano(World Health Organization), Silke Buda(Robert Koch Institute), AnnaSara Carnahan(Swedish Institute), Mariëtte Hooiveld(Netherlands Institute for Health Services Research), Mihaela Lazăr, Lisa Domegan(Health Service Executive), Jesús Castilla(Instituto de Salud Pública de Navarra), Marine Maurel, Jeff Connell(University College Dublin), Juan Antonio Linares Dópido, Ana Paula Rodrigues(Microsoft (Brazil)), Frederika Dijkstra(National Institute for Public Health and the Environment), Maria Elena Mihai, Adam Meijer(National Centre for Infectious Diseases), Daniel Castrillejo(Consejería de Educación de la Junta de Castilla y León), Francisco Pozo(Instituto de Salud Carlos III), Ralf Dürrwald(IDT Biologika (Germany)), Sanja Kurečić Filipovićović(Hrvatski zavod za javno zdravstvo), Luise Goerlitz(Robert Koch Institute), Ausenda Machado(National Institute of Health Dr. Ricardo Jorge), Vesna Višekruna Vučina(Hrvatski zavod za javno zdravstvo), Alessandra Falchi(Université de Corse Pascal Paoli), Neus Latorre‐Margalef(Public Health Agency of Sweden), Maximilian Rieß(Paul Ehrlich Institut), Raquel Guiomar, Clara Mazagatos(Instituto de Salud Carlos III), Joan O’Donnell(Health Service Executive), Ajibol Omokanye(European Centre for Disease Prevention and Control), Iván Martínez‐Baz(Instituto de Salud Carlos III), Maja Ilić(Hrvatski zavod za javno zdravstvo), Sylvie van der Werf(Centre National de la Recherche Scientifique), Ana‐Maria Vilcu(Inserm), Alina-Elena Ivanciuc(Institute for Research and Development)
Unknown
October 21, 2022
Cited by 1


Related Papers